Discover a New Class of Non-Opioid, Oral Drugs to Treat Pain and Inflammation
At EicOsis, we are developing a new class of effective pain-relieving and anti-inflammatory oral drugs without the undesirable side effects of currently available drugs. EC5026 is our first human drug candidate for pain.
EC5026 is a First-in-Class, Non-Opioid, Oral Analgesic
Our lead drug, EC5026, targets acute and chronic pain arising from a wide range of medical conditions and is designed for once daily dosing. EC5026 addresses the urgent need for a safer, non-addictive, effective analgesic and has been advanced to first-in-human clinical trials since December 2019.
Key Advantages of EC5026
A Unique Solution for Pain and Inflammation
Soluble epoxide hydrolase (sEH) inhibitors, including EC5026, hold key advantages:
Strong preclinical activity, including in naturally occurring animal pain and inflammatory conditions
Lack of common side effects of current analgesics and anti-inflammatories
sEH inhibitors do not appear to be sedating or have addiction potential
sEH inhibitors have demonstrated safety in multiple clinical trials
EC5026 Works by Increasing the Levels of Natural Analgesic and Anti-Inflammatory Molecules
EC5026 regulates the activity of powerful analgesic and anti-inflammatory fatty acids called epoxyeicosatrienoic acids (EETs) that are present in all cells in humans and animals. EC5026 inhibits the soluble epoxide hydrolase (sEH) enzyme, responsible of rapidly eliminating EETs. By inhibiting sEH, EC5026 increases the levels of EET levels at high anti-inflammatory and analgesic levels for 24 hours or longer.
Preclinical studies suggest that sEH inhibitors can decrease pain and inflammation and do not appear to produce sedation, cognitive dysfunction or other side effects common to currently available analgesics.
EC5026 is currently undergoing Phase 1 clinical trials
EicOsis received IND clearance from the FDA for EC5026 in October 2019. Phase 1a clinical trials in human volunteers started in December 2019, showing a favorable safety and pharmacokinetic profile, with no drug-related side effects. EicOsis is currently conducting additional Phase 1 clinical trials and is planning on evaluating EC5026 in pain patients soon.